Pfizer Announces That Topline Results In The Phase 3 MagnetisMM-32 Trial Of ELREXFIO Demonstrated Clinically Meaningful And Statistically Significant Benefit For Patients Whose Disease Progressed After Anti-CD38 Therapy And Lenalidomide, With Median PFS Not Yet Reached

Loading news article.

Pfizer Announces That Topline Results In The Phase 3 MagnetisMM-32 Trial Of ELREXFIO Demonstrated Clinically Meaningful And Statistically Significant Benefit For Patients Whose Disease Progressed After Anti-CD38 Therapy And Lenalidomide, With Median PFS Not Yet Reached | WAPE

Pfizer Announces That Topline Results In The Phase 3 MagnetisMM-32 Trial Of ELREXFIO Demonstrated Clinically Meaningful And Statistically Significant Benefit For Patients Whose Disease Progressed After Anti-CD38 Therapy And Lenalidomide, With Median PFS Not Yet Reached

Article summary

Related companies

Comments —